Evaluating Outcomes of Live‐Attenuated Vaccine Administration in Pediatric Patients on Dupilumab for Atopic Dermatitis

ABSTRACT Dupilumab is an IL‐4R α and IL‐13 inhibitor FDA‐approved for the treatment of atopic dermatitis (AD) in patients 6 months and older. Guidelines recommend against live‐attenuated vaccines due to limited safety data. We conducted a retrospective chart review of 233 patients aged 6 months to 10 years receiving dupilumab for AD at Children's Wisconsin, which showed that 19 received live vaccines during the study period. Four patients reported adverse events, including one requiring hospitalization. This study aims to evaluate the effects of live vaccines in children on dupilumab therapy and to assess associated adverse events, including in patients receiving their primary series of vaccines, a setting not previously described.